ArticleAnnals of hematology2025
Thromboembolism in adult patients with acute promyelocytic leukemia: clinical characteristics, risk factors, and a predictive nomogram.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dynamic white blood cell kinetics enable early risk stratification of differentiation syndrome in low- and intermediate-risk acute promyelocytic leukemia.Frontiers in oncology · 2026Article
- Risk prediction model for thrombosis in leukemia patients: a systematic review.Frontiers in oncology · 2026Review
- Establishment and validation of a 28-day clinical outcome prediction model for acute promyelocytic leukemia based on an early platelet-coagulation factor combined transfusion strategy.American journal of cancer research · 2026Article
- Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia - A Single-Center Experience from the GCC Region.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) is typically associated with bleeding, whereas thromboembolism (TE) is a less common cause of early death (ED) and frequently underestimated complication. To investigate the clinical characteristics and predictive risk factors for TE, we conducted this retrospective study. Our study included 306 patients diagnosed with APL at the Second Hospital of Shanxi Medical University between May 2012 and May 2023. Among them, 16(5.2%) patients (11 males and 5 females, with a median age of 58 years) experienced TE, including 13 cases of arterial TE (10 cerebral infarctions and three myocardial infarctions), one case of combined arterial and venous TE, and two cases of venous TE. Multivariate logistic regression analysis revealed age (OR 1.08, 95% CI 1.03-1.13, p = 0.001), smoking (3.26, 1.01-10.49, p = 0.048), alkaline phosphatase (ALP) > 125U/L (10.8, 2.26-51.46, p = 0.021), and serum creatinine (SCr) > 62µmol/L (7.09, 1.35-37.35, p = 0.003) as independent risk factors for TE in newly diagnosed APL patients. A nomogram incorporating the four aforementioned predictive factors demonstrated high accuracy and clinical applicability. With a median follow-up of 6.6 years (range: 0.6-11.8 years), the overall survival (OS) rate for all patients was 86.2%. When excluding patients who succumbed to ED, the OS rate increased to 96.2%. Importantly, there was no statistically significant difference in OS rates between non-ED patients with and without TE (p = 0.405). Our findings underscore that age, smoking, ALP, and SCr are four independent risk factors for TE in APL. Furthermore, TE primarily affects early survival but not OS rates in APL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.